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Introduction
Despite the marked improvement of treatment outcomes for multiple myeloma (MM) during the last decade through the development of new therapeutic modalities such as bortezomib (BTZ) and immunomodulatory derivatives (IMiDs) (1), MM remains mostly incurable due to both cell-intrinsic and -extrinsic drug resistant mechanisms. The former is induced by highly complex and heterogeneous molecular abnormalities (2, 3) , while the latter is generated by various myeloma microenvironment factors, such as soluble factors, or adjacent bone marrow (BM) stromal cells (4, 5) . Therefore, the search for a therapeutic target molecule where various types of signaling for myeloma cell survival converge is essential for the development of a more effective therapy for MM.
RSK2 is a member of the 90 kDa ribosomal S6 kinase family of serine/threonine (Ser/Thr) kinases that regulates diverse cellular processes, such as cell proliferation, cell motility, or cell survival (6) . In hematopoietic system, RSK2 is phosphorylated in B and T lymphocytes in physiologic condition, while its further phosphorylation has been shown to be essential in their activation (7, 8) . It is located downstream of the RAS/ERK1/2 signaling cascade, RSK2 as therapeutic target for myeloma respectively) (19) . Cells were maintained in RPMI-1640 containing 10% fetal calf serum (FCS), 2mM L-glutamate and penicillin/streptomycin. Subclones of OPM-2 and KMS-11 (OPM-2/BTZ and KMS-11/BTZ), which are resistant to BTZ, were developed under continuous exposure to BTZ in the same medium over half a year. These cells acquire BTZ resistance by a mutation of gene encoding proteasome beta5 subunit which suppresses apoptotic signals through the inhibition of unfolded protein accumulation and subsequent excessive ER stress (20) . No further authentication was carried out. Studies using patient samples were approved by the Ethics Review Board of our institute. BM mononuclear cells were labeled with anti-CD138 MicroBeads and positively isolated with the MiniMACS separator (Miltenyi Biotec KK, Tokyo, Japan) (21) . Isolated myeloma cells were cultured with 50 ng/ml interleukin-6 (IL-6). BI-D1870, an RSK2
inhibitor, was purchased from Symansis NZ Limited (Auckland, New Zealand).
Z-VAD-FMK, a pan-caspase inhibitor, from Calbiochem (San Diego, CA, USA).
MS-275, a histone deacetylase inhibitor (DACI), from Selleck Chemicals (Houston, TX, USA), and ABT-263, a BH3-mimic inhibitor for BCL2/BCLX L , from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Lenalidomide (LEN) was supplied by Celgene Corporation (Summit, NJ, USA), and BTZ, adriamycin (ADR), melphalan (L-PAM), U0126, an inhibitor for MEK, and everolimus (RAD001), an inhibitor for mTOR, by the Screening Committee of Anticancer Drugs (Tokyo, Japan) ( Fig. 1 ).
RNA interference (RNAi)
RNAi for RSK2 was performed by transfecting small interfering RNA 
Assays for growth inhibition and apoptosis
Assays for growth inhibition and apoptosis were performed as previously described (21, 22) with z-VAD-FMK did not diminish the anti-MM effect of BI-D1870 on NCI-H929 cells (Fig. 3E ). These findings indicate that RSK2 Ser227 inhibition by BI-D1870
(Supplementary information).

Results
RSK2
causes both caspase-related and -unrelated apoptosis in NCI-H929 cells.
Ser227 is phosphorylated in primary MM cells with and without t(4;14)
We also examined the phosphorylation status of RSK2 
ABT-263, at a wide range of fractional effect concentrations (Fig. 6C) .
Discussion
We initially hypothesized that RSK2 may be activated by various cell-intrinsic and -extrinsic stimuli, such as genetic and/or molecular oncogenic abnormalities or different growth factor-mediated signals, however, we unexpectedly found that RSK2 Ser227 , which is a site responsible for substrate to develop a novel RSK2 NTKD-specific inhibitor which can be used for a preclinical study for myeloma.
In conclusion, the findings of this study suggest that RSK2 Ser227 in an N-terminal kinase domain is a potential general therapeutic target for MM.
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